In asthma and chronic obstructive pulmonary disease, activation of G q -protein-coupled receptors causes bronchoconstriction. In each case, the management of moderate-to-severe disease uses inhaled corticosteroid (glucocorticoid)/long-acting β 2 -adrenoceptor agonist (LABA) combination therapies, which are more efficacious than either monotherapy alone. In primary human airway smooth muscle cells, glucocorticoid/LABA combinations synergistically induce the expression of regulator of G-protein signaling 2 (RGS2), a GTPaseactivating protein that attenuates G q signaling. Functionally, RGS2 reduced intracellular free calcium flux elicited by histamine, methacholine, leukotrienes, and other spasmogens. Furthermore, protection against spasmogen-increased intracellular free calcium, following treatment for 6 h with LABA plus corticosteroid, was dependent on RGS2. Finally, Rgs2-deficient mice revealed enhanced bronchoconstriction to spasmogens and an absence of LABA-induced bronchoprotection. These data identify RGS2 gene expression as a genomic mechanism of bronchoprotection that is induced by glucocorticoids plus LABAs in human airway smooth muscle and provide a rational explanation for the clinical efficacy of inhaled corticosteroid (glucocorticoid)/LABA combinations in obstructive airways diseases.
β 2 -Adrenoceptor agonist-induced RGS2 expression is a genomic mechanism of bronchoprotection that is enhanced by glucocorticoids In asthma and chronic obstructive pulmonary disease, activation of G q -protein-coupled receptors causes bronchoconstriction. In each case, the management of moderate-to-severe disease uses inhaled corticosteroid (glucocorticoid)/long-acting β 2 -adrenoceptor agonist (LABA) combination therapies, which are more efficacious than either monotherapy alone. In primary human airway smooth muscle cells, glucocorticoid/LABA combinations synergistically induce the expression of regulator of G-protein signaling 2 (RGS2), a GTPaseactivating protein that attenuates G q signaling. Functionally, RGS2 reduced intracellular free calcium flux elicited by histamine, methacholine, leukotrienes, and other spasmogens. Furthermore, protection against spasmogen-increased intracellular free calcium, following treatment for 6 h with LABA plus corticosteroid, was dependent on RGS2. Finally, Rgs2-deficient mice revealed enhanced bronchoconstriction to spasmogens and an absence of LABA-induced bronchoprotection. These data identify RGS2 gene expression as a genomic mechanism of bronchoprotection that is induced by glucocorticoids plus LABAs in human airway smooth muscle and provide a rational explanation for the clinical efficacy of inhaled corticosteroid (glucocorticoid)/LABA combinations in obstructive airways diseases.
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A sthma affects up to 300 million people globally, and chronic obstructive pulmonary disease (COPD), which is predominantly caused by cigarette smoking, is predicted to become the third leading cause of death. Both diseases are characterized by airflow limitation due, at least in part, to bronchoconstriction. Therapeutically, long-acting β 2 -adrenoceptor agonists (LABAs), short-acting β 2 -adrenoceptor agonists (SABAs), and inhaled glucocorticoids, clinically known as inhaled corticosteroids (ICSs), represent cornerstone treatments for both asthma and COPD (1, 2) . Whereas SABAs provide short-term symptomatic relief of bronchospasm, international practice guidelines recommend ICS/ LABA combination inhalers for asthma patients whose symptoms are not adequately controlled on ICS monotherapy (1) . Moreover, clinical guidelines recommend long-acting bronchodilators as a first-line therapy for mild COPD and ICS/LABA combinations for more severe disease (1, 2) . In each case, large, multicenter randomized controlled clinical trials convincingly show enhanced clinical benefits to ICS/LABA combinations that are not achieved by either component alone (2) (3) (4) . However, despite the benefits achieved by these combination therapies, there is a paucity of mechanistic information accounting for these effects.
Several mediators, including acetylcholine, histamine, cysteinylleukotrienes, and certain prostanoids, promote bronchoconstriction, which is a defining characteristic of asthma and COPD (1, 2, 5) . Such mediators contract airway smooth muscle (ASM) by activating G-protein-coupled receptors (GPCRs) that typically signal to phospholipase Cβ via the heterotrimeric G protein, G q (6, 7) . This leads to the formation of inositol (1, 4, 5) ] i ) from internal stores, and diacylglycerol, an activator of protein kinase C, which, together with IP 3 , promotes ASM contraction (6, 7) . Conversely, β 2 -adrenoceptor agonists are bronchodilators that functionally antagonize ASM contraction irrespective of the constrictor (8) . Current dogma holds that β 2 -adrenoceptor agonism activates the cAMP/cAMP-dependent protein kinase A (PKA) pathway to phosphorylate downstream targets that oppose actin-myosin cross-bridge formation and reduce ASM force generation (8) .
Signaling from GPCRs is terminated by GTPase-activating proteins (GAPs) (9) , which enhance the rate at which Gα subunits hydrolyze GTP. We show that the expression of the regulator of Gprotein signaling 2 (RGS2), a G q selective GAP (10, 11) , is transcriptionally up-regulated by LABAs and that this is enhanced and prolonged by glucocorticoids in human ASM. In vitro RGS2 down-regulates signaling from multiple G q -coupled receptors and in vivo imparts bronchoprotection against spasmogens. Increased RGS2 gene expression therefore represents a genomic mechanism of bronchoprotection, which may contribute to the therapeutic activity of ICS/LABA combination therapies.
Results

RGS2 Expression Is Induced by LABAs and Enhanced by Glucocorticoids.
Primary human ASM cells were treated with maximally effective concentrations of dexamethasone, the LABAs, salmeterol xinafoate (salmeterol), formoterol fumarate (formoterol), and the adenylyl cyclase activator, forskolin, before analysis for RGS2 mRNA (Fig. 1A and Fig. S1A ) (12) . Although RGS2 mRNA was modestly induced by dexamethasone at all times, the LABAs significantly induced RGS2 expression at 1 and 2 h, and forskolin induced RGS2 mRNA at all times tested. In the presence of LABAs or forskolin, dexamethasone significantly enhanced RGS2 expression at 1 and 2 h. This effect was more than the sum of the components and is therefore described as synergy. At 6 h, neither LABAs nor dexamethasone significantly increased RGS2 mRNA, yet the combination significantly induced RGS2 mRNA.
To explore the mechanistic basis for this effect, unspliced nuclear RNA (nRNA) corresponding to the exon 1-intron A and exon 4-intron D splice junctions in RGS2 was examined as an index of transcription rate (Fig S1B) . Because splicing reactions are not limiting and occur very rapidly (13), the transient accumulation of unspliced nRNA is a surrogate of transcription rate (14, 15) . TaqMan PCR for the RGS2 exon 1-intron A slice junction revealed a very rapid increase induced by salmeterol that was further enhanced by dexamethasone (Fig. 1A) . This effect had declined by 6 h, but in the presence of dexamethasone was still significantly induced. An identical effect was observed for the RGS2 exon 4-intron D junction (Fig. S1C ).
To examine a role for mRNA stability, ASM cells were tested in standard actinomycin D chase experiments. Following either no treatment or stimulation with dexamethasone, salmeterol, or salmeterol plus dexamethasone for 2 h, actinomycin D was added, and decay of RGS2 mRNA was monitored by real-time RT-PCR (Fig. 1B) . No significant changes in RSG2 mRNA stability were detected between any treatment group. Taken with the nRNA data, this clearly shows the increased RGS2 mRNA expression due to LABAs and that the enhancement and prolonged expression in the presence of glucocorticoid are primarily due to the modulation of gene transcription.
RGS2 protein expression revealed variable and barely detectible increases by the glucocorticoids, fluticasone propionate (FP), budesonide, and dexamethasone ( Fig. 1C; Fig. S2 A and B; Fig.  S3A ). Conversely, salmeterol and formoterol strongly induced RGS2 expression, which peaked at 2 h ( Fig. 1C; Figs. S2 and S3 ). This was mimicked by forskolin, but the duration of RGS2 expression was prolonged. The presence of FP further elevated salmeterol-and forskolin-induced RGS2 expression at 1 and 2 h, and, at times thereafter, RGS2 expression was dramatically prolonged (Fig. 1C) . Indeed, salmeterol plus FP induced RGS2 protein from 45 min to 18 h posttreatment, with a plateau of near maximal expression between 2 and 8 h (Fig. 1D and Fig. S2 ). Similar data were described for salmeterol plus dexamethasone and formoterol plus budesonide (Figs. S2 and S3) . The up-regulation of RGS2 expression by salmeterol or by salmeterol plus FP was attenuated by the β 2 -adrenoceptor selective antagonist, ICI 118,551 (Fig. S3C) . This confirms the selectivity for the β 2 adrenoceptors. Similarly, the ability of salmeterol or salmeterol plus dexamethasone to induce RGS2 expression was totally prevented by the RNA polymerase II inhibitor, actinomycin D, and is consistent with transcriptional control (Fig. S3D) .
To explore the role of PKA, cells were infected with adenovirus overexpressing PKIα, a highly selective and potent inhibitor of PKA (16) . Using this method, virtually all ASM cells express PKIα, and this inhibits cAMP response element (CRE) binding protein (CREB) phosphorylation and CRE-dependent transcription (17, 18) . Induction of RGS2 protein by salmeterol was blocked by Ad5-PKIα, but not by the control Ad5-lacZ (Fig. 1E ). In the presence of salmeterol plus FP, RGS2 protein was strongly induced and was also inhibited by Ad-PKIα, but not by Ad5-LacZ (P < 0.001 relative to either naive or Ad5-LacZ using ANOVA with a Bonferroni post test). These data support a PKA-dependent mechanism for the induction of RGS2 by LABAs. ] i with near maximal responses at 10 μM ( Fig. 2A ). This was blocked by mepyramine, a histamine H 1 receptor antagonist (19) , and 2-aminoethyldiphenyl borate (2-APB), an IP 3 R antagonist (20) (Fig. 2B ). Because the H 1 receptor couples to G q (19) , this confirms a G q /IP 3 /IP 3 R pathway linked to [Ca 2+ ] i flux. Similarly, the acetylcholine analog, methacholine, contracts ASM via the Gq-linked muscarinic M 3 receptor (6, 19 ). In the current study, methacholine-induced [Ca 2+ ] i was maximal at 30 μM and was blocked by 2-APB ( Fig. S4 A and  B) . Likewise, the thromboxane analog, U46619, which is selective for the G q -linked thromboxane receptor (TP) (19) , maximally increased [Ca 2+ ] i at 1 μM and this was blocked by 2-APB, again supporting a conventional G q -linked pathway leading to elevated [Ca 2+ ] i ( Fig. S4 C and D) . Because RGS2 expression was maximal 2 h after LABA addition and because this was prolonged to at least 6 h by glucocorticoid, the protective role of these treatments was tested on spasmogen-increased [Ca 2+ ] i . Following a 2-h pretreatment, salmeterol and salmeterol plus dexamethasone, but not dexamethasone alone, significantly attenuated histamine-, methacholine-, or U46619-induced [Ca 2+ ] i (Fig. 2C) . However, after a 6-h pretreatment, only salmeterol plus dexamethasone significantly attenuated histamine-, methacholine-, and U46619-induced increases in [Ca 2+ ] i relative to control, salmeterol, or dexamethasone alone (Fig. 2C ). To explore this effect, ASM cells were pretreated with dexamethasone, salmeterol, or salmeterol plus dexamethasone for various times before stimulation with histamine ( Fig. 2D) ] i following 1-, 2-, and 4-h pretreatments, and salmeterol plus dexamethasone provided significant protection with 1-to 12-h pretreatments (Fig. 2D ). This , expressed as RGS2/GAPDH, are plotted as fold relative to untreated (at t = 1 h) as means ± SE. (Lower) Data (n = 10) are plotted as nRGS2/U6 as means ± SE. Multiple comparisons at each time were made using ANOVA with a Bonferroni post test. Significance data relative to untreated samples are *P < 0.05, **P < 0.01, and ***P < 0.001. Significance data relative to Dex-treated samples are a P < 0.05, b P < 0.01, and illustrates the enhanced protective effect afforded by the LABA/ glucocorticoid combination. ] i flux elicited by histamine ( Fig. 3 A and  B) . At all MOIs, repression was significant relative to Ad5-LacZ and was reproduced for methacholine and U46619 (Fig. 3B and  Fig. S4E) . Similarly, bradykinin, LTB 4 , LTD 4 , and misoprostol, which act on the G q -linked B 1 and B 2 , BLT 1 and BLT 2 , CysLT 1 and CysLT 2 , and EP 3 receptors, respectively (19) , all elicited increased [Ca 2+ ] i that was significantly repressed by Ad5-RGS2, but not by LacZ-expressing virus (Fig. S4F) . Importantly, KCl-induced [Ca 2+ ] i , a receptor-independent stimulus, was unaffected by Ad5-RGS2 (Fig. 3C) . Thus, RGS2 attenuates procontractile responses produced by G q -linked GPCR agonists in primary human ASM cells.
Repression of [Ca
Gene silencing by two targeting, but not control, siRNAs robustly reduced salmeterol plus dexamethasone-induced RGS2 expression (Fig. 3D) . Following a 6-h incubation with salmeterol plus dexamethasone, repression of histamine-increased [Ca 2+ ] i was evident in naive and control siRNA-treated cells (Fig. 3E and  Fig. S4G) . However, the two RGS2-targeting siRNAs prevented this, and equivalent effects were shown for methacholine and U46619 (Fig. 3E and Fig. S4G ). Conversely, 2 h of salmeterol plus dexamethasone repressed agonist-increased [Ca 2+ ] i , but this was unaffected by RGS2-targeting siRNAs (Fig. S4G) . Because RGS2 is strongly expressed at both times ( Fig. 1 and Fig. S3 ), we propose that RGS2 is an essential and primary effector of repression at 6 h, but that non-RGS2 repressive mechanisms exist with shorter treatments.
RGS2 Is Bronchoprotective. Given a causal relationship between elevated [Ca 2+ ] i and ASM contraction (6, 7), the above data imply that RGS2 prevents ASM contraction. This was tested in an experimental model using Rgs2-deficient (Rgs2 (Fig. S5A) (21) . Following PCR genotyping (Fig. S5 A and  B) , tracheas were removed for analysis of isometric force generated by the trachealis muscle (Fig. 4A ). Methacholine concentration dependently increased tension in wild-type animals with a peak of 294 ± 22% compared with the effect of 100 mM KCl. With trachealis from Rgs2 −/− littermates, methacholine achieved greater peak tensions (523 ± 104%) (Fig. 4A) . Rgs2 protein was expressed in wild type, but not in Rgs2 −/− tracheas (Fig. 4A, Lower) .
Lung function of wild-type, Rgs2 +/− , and Rgs2 −/− animals was compared using the SciReq Flexivent system (22) . Lung resistance and compliance were measured at baseline, following inhalation of nebulized PBS, methacholine, or 5-hydroxytryptamine (5-HT) (Fig. 4B) . No differences in baseline resistance, or following PBS inhalation, were detected between wild-type, heterozygote, or knockout animals. Increasing methacholine doses modestly increased resistance in wild-type animals, and this was significantly enhanced in Rgs2 −/− animals (Fig. 4B ). Heterozygotes revealed an intermediate phenotype. Similar data were obtained for 5-HT except that knockout animals showed elevated resistance at all 5-HT doses (Fig. 4B) . Lung compliance (inverse of stiffness) was significantly lower in knockout and heterozygote animals compared with wild-type counterparts (Fig. 4B) . In response to inhaled methacholine or 5-HT, all animals showed reduced compliance. Knockout animals exhibited the lowest compliance, and heterozygotes were an intermediate phenotype.
Graded expression of Rgs2 was confirmed (Fig. S5C) . Because pathology may affect lung function, lungs were removed for histological examination by hematoxylin and eosin staining (for inflammation), periodic acid Schiff staining (for mucus), and differential cell counting in bronchoalveolar lavage fluid. No differences were detected between wild-type, Rgs2 +/− , and Rgs2 −/− mice (Fig. S6) .
In cultured mouse tracheal cells (MTCs) expressing the smooth muscle markers α-smooth muscle actin and calponin (Fig. S7A) , salmeterol plus dexamethasone induced Rgs2 expression and reduced methacholine-, U46619-, and 5-HT-induced increases in [Ca 2+ ] i (Fig. S7 B and C) . Conversely, in Rgs2 −/− MTCs, there was no Rgs2 and no protection by salmeterol plus dexamethasone against agonist-increased [Ca 2+ ] i (Fig. S7 B and C) . Although this establishes a functional role for Rgs2 in MTCs, regulation of mouse Rgs2 differed from human ASM cells. Whereas salmeterol induced Rgs2 protein with similar kinetics to human ASM and via the β 2 -adrenoceptor (Fig. S7 D and E) , there was no dexamethasone enhancement in MTCs. Therefore, LABA alone was used in vivo to induce Rgs2 expression. Two hours following intratracheal (i.t.) administration of aerosolized formoterol, there was a dose-dependent protection against methacholine-induced resistance and loss of compliance that min before a 10-μM histamine challenge. Data (mep, n = 6; 2-APB, n = 8) are plotted as means of F/F 0 ± SE. Significance was tested using a Student's t test where *P < 0.05 and ***P < 0.001. (C) Cells were treated as in A, except that 100 nM salmeterol (Salm) and/or 1 μM dexamethasone (Dex) were added 2 or 6 h before 10 μM histamine, 30 μM methacholine (MCh), or a 1-μM U46619 challenge. Data (2 h pretreatment, n = 4; 6 h pretreatment, n = 8-10) expressed as peak F/F 0 are plotted as means ± SE. Multiple comparisons were made using ANOVA with a Bonferroni post test. Significance data relative to untreated samples are a P < 0.05, b P < 0.01, and c P < 0.001. Significance data relative to Dex-treated samples are d P < 0.05, e P < 0.01, and f P < 0.001. Significance between other groups is indicated where ***P < 0.001. (D) Cells were pretreated with Dex (1 μM), Salm (100 nM), or Dex (1 μM) + Salm (100 nM) for the indicated times before challenge with histamine (10 μM) and measurement of fluorescence. Peak F/F o is plotted as means ± SE. Significance relative to F/F o induced by histamine was tested by ANOVA with a Dunnett's post test. **P < 0.01; ***P < 0.001. correlated with Rgs2 expression (Fig. S8) . Wild-type and Rgs2 −/− animals were therefore treated with i.t. formoterol for 2 h before lung function analysis. Methacholine increased lung resistance and reduced compliance in wild-type animals, and formoterol significantly protected against these effects (Fig. 4C) . In Rgs2 −/− animals, the changes in lung function induced by methacholine were unaffected by formoterol. Basal and formoterol-induced Rgs2 expression was confirmed in the lungs of wild-type, but not of Rgs2 −/− , animals (Fig. 4C) . Thus, elevated RGS2 protects against methacholine-induced increases in lung resistance and loss of compliance.
Discussion
We describe the induction of RGS2 expression as a previously unrecognized genomic mechanism of bronchoprotection that is induced by LABAs and that is synergistically enhanced by glucocorticoids in human ASM cells. We propose that this represents an important means by which ICS/LABA therapies effect superior control of symptoms in diseases such as asthma or COPD. Thus, international guidelines for the management of asthma and COPD indicate stepwise increases in the intensity of pharmacotherapy moving from inhaled monotherapies to inhaled ICS/LABA combinations (1, 2). For example, mild-to-moderate asthmatics are generally prescribed regular ICS whereas more severe disease requires ICS/LABA combinations, which enhance the therapeutic effectiveness of the ICS to a level that cannot be achieved by ICS alone (23) . Conversely, in COPD, LABAs represent an initial maintenance medication, which, in more advanced disease, is increased to ICS/LABA combinations. Equally, bronchiolitis is a major cause of hospitalization in infants of less than 1 y and is poorly controlled by conventional monotherapies (24) . However, inhaled epinephrine, which will activate β 2 -adrenoceptors on ASM, combined with dexamethasone (epinephrine and dexamethasone were ineffective alone), significantly reduced hospitalization rates in these infants (25) . Thus, multiple strands of clinical evidence support a positive, synergistic interaction between the agonist of the β 2 -adrenoceptor and the glucocorticoid receptor (GR). Our current study offers some explanation for this effect (23) . Mechanistically, β 2 -adrenoceptor agonists can synergistically enhance glucocorticoid actions, and this may contribute to the enhanced efficacy of ICS/LABA combinations (12, 23) . However, we show RGS2 to be a PKA-dependent effector gene, whose expression in human ASM promotes bronchoprotection and is synergistically enhanced by glucocorticoids. Functionally, RGS2 is a GAP that switches off signaling from G q -coupled GPCRs (10, 26) , including muscarinic M 1 and M 3 receptors (27, 28), and we confirm this for multiple other receptors that are relevant to lung disease. Importantly, combinations of LABA plus glucocorticoid enhance and extend RGS2 expression in human ASM, and loss of RGS2 expression prevents the prolonged protective effect of the combination against agonist-enhanced [Ca 2+ ] i . In vivo, loss of RGS2 produces a hyperactive phenotype with increased lung resistance and reduced compliance. This is consistent with the hypertensive effect of RGS2 loss in the vasculature and confirms a bronchoprotective role in the lung (29, 30) . Furthermore, the ability to induce RGS2 expression in vivo further protects against spasmogen-increased lung resistance and reductions in compliance. Thus, the extended induction of RSG2 in ASM by ICS/ LABA combination therapies should provide superior protection from multiple spasmogens that act on G q -coupled GPCRs in asthma, COPD, or bronchiolitis and other diseases.
Induction of RGS2 expression by β 2 -adrenoceptor agonists and forskolin implies a classical cAMP pathway leading rapidly to RGS2 gene expression and is consistent with isoproterenol inducing RGS2 mRNA in rat astrocytoma cells (31) . Roles for the β 2 -adrenoceptor and PKA were confirmed by preventing RGS2 expression in the presence of ICI 118,551 or PKIα and is supported for forskolin, which induces CREB binding to CRE sites in the proximal RGS2 promoter (32) . Likewise, the ability of glucocorticoids to synergistically enhance RGS2 expression could simplistically involve enhanced β 2 -adrenoceptor expression, coupling, or reduced receptor desensitization (see ref. 8 and references therein). However, these effects are not likely to occur acutely and in any event may not be important in ASM due to the large β 2 -adrenoceptor reserve (33) . More likely, as RGS2 is a glucocorticoid-responsive gene (15, 34) with an established GR-binding region (35) , there is a direct interaction of the cAMP and glucocorticoid pathways at the level of promoter activation. Certainly, our data support a mechanism that involves transcriptional induction of RGS2 because the level of unspliced nuclear RGS2 RNA was both enhanced and prolonged in the presence of LABA plus glucocorticoid. Because there was no obvious effect on RGS2 mRNA stability, and because protein expression correlates well with mRNA expression, these data support transcriptional control as the major effector mechanism governing RGS2 expression in human ASM cells. Furthermore, the use of three structurally distinct GR ligands with differing selectivities for other nuclear hormone receptors, including the progesterone, mineralocorticoid, androgen, and estrogen receptors (4), excludes their involvement and supports a role for GR. This interaction between the glucocorticoid and cAMP pathways requires formal investigation and should be tested alongside other physiological agents, such as parathyroid hormone or angiotensin II, which also induce RSG2 expression (36, 37) .
Importantly, knockdown of RGS2 expression in human ASM cells did not prevent attenuation of spasmogen-enhanced [Ca 2+ ] i following 2 h of salmeterol plus dexamethasone. Given the presence of RGS2 protein, classical mechanisms of bronchoprotection must operate to create functional redundancy. However, the protective effect of 6 h of salmeterol plus dexamethasone on human ASM was totally prevented by RGS2 knockdown. This indicates that elevated RGS2 gene expression is the dominant protective mechanism and clearly illustrates how ICS/LABA combinations may confer enhanced therapeutic benefit. Indeed, the 12-h protection from spasmogen-induced [Ca 2+ ] i afforded by salmeterol plus dexamethasone, compared with just 4 h for salmeterol alone, further demonstrates the potential advantage due to RGS2. In this context, it is salient to note that the effects due to RGS2 occur on a background of other RGS proteins, including RGS3, -4, and -5, which are all relatively highly expressed in human ASM cells (38) . Indeed, somewhat paradoxically, β-agonists reduce RGS5 expression, and this may be expected to reduce some of the benefit conferred by elevation of RGS2 (38) .
These data also highlight important differences between mice and humans. First, human RSG2 is synergistically induced by LABAs and glucocorticoids, whereas mouse Rgs2 is induced only by LABAs. Thus, the mouse models Rgs2 function, but not gene regulation. Second, mouse Rgs2 function is nonredundant when induced by LABA alone. In this regard, there is persuasive evidence suggesting that the classical bronchodilatory effects of β-adrenoceptor agonists are mediated via the β 1 , rather than the β 2 , subtype in the mouse (39) . Thus, β 2 -adrenoceptor agonists are poor bronchodilators in the mouse, and this explains why nonselective agonists are more effective and potent bronchodilators than β 2 -selective agonists (40) . Nevertheless, our data clearly show that β 2 -adrenoceptor agonists induce the expression of Rgs2 and that this leads to a significant nonredundant bronchoprotective effect that is absent in Rgs2 −/− animals. In summary, the induction of RGS2 gene expression provides bronchoprotection, which, in the context of β 2 -adrenoceptor monotherapy, is likely to be largely redundant because of acute, nongenomic mechanisms of relaxation/bronchoprotection. However, in the clinical context of ICS/LABA combination therapies, RGS2 expression may be enhanced and prolonged. Under this condition, the genomic induction of RGS2 becomes the predominant effector for protecting against bronchoconstrictor mediators. This represents a fundamental shift in our understanding of how sympathomimetic bronchodilators improve symptom control in diseases such as asthma, COPD, or acute bronchiolitis. In terms of drug discovery, drugs, or drug combinations, that enhance and/or prolong RGS2 expression are, like ICS/LABA combinations, predicted to result in superior bronchoprotection from clinically relevant spasmogens.
Materials and Methods
Materials. Reagents were from Sigma-Aldrich unless otherwise specified. C57/Bl6 wild-type, Rgs2 heterozygous (Rgs2 +/− ), and knockout (Rgs2 −/− ) mice were bred in-house through Rgs2 +/− × Rgs2 +/− crosses (21, 30) . Protocols were approved by the University of Calgary Animal Care Committee, according to the Canadian Council for Animal Care guidelines. Mice were age and sex matched between different genotype groups. Where appropriate, mice were anesthetized with isofluorane before i.t administration of aerosolized 0.9% NaCl or formoterol using a MicroSprayer aerosolizer (Penn-Century) (41) . Isolated ASM cells from normal human lungs were grown in Dulbecco's Modified Eagle Medium (Invitrogen) and incubated in serum-free medium before experiments (12) .
RNA Isolation and Real-Time PCR. RNA extractions and real-time PCR (SYBR GreenER chemistry) for GAPDH was as described (15) . Amplification primers were RGS2 forward (5′-CCT CAA AAG CAA GGA AAA TAT ATA CTG A-3′) and reverse (5′-AGT TGT AAA GCA GCC ACT TGT AGC T-3′). TaqMan analysis of unspliced nuclear RGS2 is described in SI Materials and Methods.
Western Blotting, siRNA Knockdown, and Adenoviral Infections. Western blotting, siRNA transfections, and adenoviral infections were as described (42) . siRNA-targeted sequences were RGS2 siRNA 2 (SI00045773; 5′-AAC GTG GTG TCT CAC TCT GAA-3′); RGS2 siRNA 6 (SI03036082; 5′-AAG GGT ATA CAG CTT GAT GGA-3′) (Qiagen); and green fluorescent protein siRNA (control siRNA) (P-002048-03-20; 5′-GGC AAG CTG ACC CTG AAG TTC-3′) (Dharmacon). Cells were infected with 300 MOI of Ad5-RGS2.HA (43) Lung Function. Mice were anesthetized by intraperitoneal injection of sodium pentobarbital (50 mg/kg) (CEVA Santé Animale) and intramuscular injection of ketamine hydrochloride (90 mg/kg) (Wyeth). Tracheostomized mice were connected to a flexivent small animal ventilator (SciReq) before challenge with increasing concentrations of aerosolized drugs administered via an inline nebulizer. Resistance and compliance were measured using a snapshot 150 perturbation (22) .
Isometric Force Measurement. Mice were euthanized with 200 mg/kg pentobarbital and exsanguination. Excised tracheas were divided into four equal pieces before placing in oxygenated Krebs-Henseleit solution (KHS) (33) . Strips were mounted vertically under a tension of 6 mN in oxygenated KHS at 37°C. After equilibration with frequent washing for at least 120 min before experiments, changes in tension were measured isometrically (33) .
